Efficient, reproducible production of mRNA-based medicines depends on a well-designed continuum spanning plasmid DNA (pDNA) preparation, in vitro transcription (IVT), and lipid nanoparticle (LNP) formulation.
Attend this webinar to:
Learn how in-line lysis approaches compare with batch methods in maintaining plasmid quality and scalability
Explore which factors most strongly drive IVT efficiency and how they can be adjusted to minimize double stranded (dsRNA) formation
Understand the dual role of oligo dT in maximizing mRNA recovery and supporting impurity removal
Learn about novel chromatographic LNP manufacturing techniques that improve and simplify your process
Discover approaches for generating meaningful analytical data to characterize LNP formulations with confidence
Collectively, these insights will provide a roadmap for developing nucleic acid processes that are scalable, robust, and aligned with regulatory expectations.